COLORADO SPRINGS, Colo., Oct. 9 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has received reimbursement approval from the competent governmental authority in Belgium for its lead removal and peripheral atherectomy product line, effective October 1, 2007.
The reimbursement for the lead removal indication -- an embedded, infected lead or an electronic malfunction of a pacemaker or defibrillator electrode -- applies to hospitals in Belgium that meet the national cardiac pathology requirements and standards. The reimbursement for the peripheral indication applies to all centers in Belgium equipped with Spectranetics' technology for patients that suffer from critical limb ischemia with non-healing ulcers or rest pain due to infrapopliteal disease.
Shar Matin, Managing Director of Spectranetics International, B.V. commented, "We are very pleased that the Belgian authority granted reimbursement approval for our laser-based therapies. Belgian patients now have greater access to our life-changing technology. Reimbursement initiatives are a cornerstone of Spectranetics International's strategy and this approval follows the reimbursement approval in Germany for our peripheral atherectomy device earlier this year."
About Spectranetics
Founded in 1984, Spectranetics manufactures and sells the only excimer
laser approved in the United States, Europe and Japan for use in minimally
invasive cardiovascular procedures. This technology treats complex
cardiovascular conditions by photo-ablating multiple lesion types into tiny
particles that are easily absorbed into the blood stream. The Company's
disposable catheters use high-energy "cool" ultraviolet light to vaporize
arte
'/>"/>
| SOURCE Spectranetics Corporation Copyright©2007 PR Newswire. All rights reserved |